Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
American Journal of Obstetrics and Gynecology|January 16, 2021
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study groupLinn Woelber, Katharina Prieske, Christine Eulenburg, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Vaccine|March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 studyElmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.
Biomedicines|December 23, 2023
Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed ImmunohistochemistryTim Mandelkow, Elena Bady, Magalie C J Lurati, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
Lancet (London, England)|December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
The New England Journal of Medicine|July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerIgnace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Geburtshilfe Und Frauenheilkunde|December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
Cancers|July 20, 2021
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment SurveillanceHeike Hoyer, Grit Mehlhorn, Cornelia Scheungraber, et al.
Pageof 11